ChemExpress Secures Rare Flawless Score in First U.S. Health Regulator Audit
Ma’anshan, Monday, 2 November 2026.
ChemExpress achieved a rare, observation-free clearance during its initial U.S. FDA audit at its Ma’anshan plant, validating the facility’s manufacturing standards for American pharmaceutical supply chains.
A Landmark Clean Audit in Global Pharmaceutical Manufacturing
On 1 November 2026, ChemExpress, a contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredients (APIs) and highly potent APIs (HPAPIs), announced that its Ma’anshan production site in Anhui Province, China, had completed its inaugural U.S. Food and Drug Administration (FDA) inspection without issuing any Form FDA 483 observations [1][2]. The zero-observation outcome represents a rare validation of the facility’s current Good Manufacturing Practice (cGMP) systems and positions the site as a preferred partner for multinational pharmaceutical clients seeking compliant API supply chains for the U.S. market. ChemExpress operates the Ma’anshan site through its wholly owned subsidiary, Anhui Haoyuan Pharmaceutical Co., Ltd., which focuses on process scale-up, cGMP manufacturing, and commercial supply of APIs and HPAPIs [1][2].
FDA Inspection Scope and Regulatory Context
The FDA inspection, conducted in August 2026 under the Agency’s Fiscal Year 2026 work plan and Compliance Program CPGM 7356.002F, evaluated six critical cGMP systems at the Ma’anshan facility: Quality, Facilities and Equipment, Materials, Production, Packaging and Labeling, and Laboratory Control [1][2]. The absence of any Form FDA 483 observations indicates full compliance across these systems, a condition observed in only a small fraction of inaugural inspections [alert! ‘exact percentage not specified in sources’]. This outcome underscores the facility’s alignment with international regulatory expectations and its readiness to support U.S.-bound pharmaceutical production [1][2].
Strategic Implications for ChemExpress and Its Partners
Dr. Yonggang Chen, Senior Vice President and Chief Technology Officer of ChemExpress, emphasized the milestone’s significance in a statement released on 1 November 2026: ‘Successfully completing our first U.S. FDA inspection with no Form FDA 483 observations is an important milestone in ChemExpress’ Ma’anshan Site’s ongoing development of an internationally aligned quality management system’ [1]. The company’s integrated service platform spans technology transfer, process scale-up, cGMP manufacturing, and commercial supply, enabling end-to-end support for global pharmaceutical innovation [1]. With the Ma’anshan site now validated for U.S. market supply, ChemExpress strengthens its competitive positioning as a CDMO capable of meeting stringent regulatory and quality standards [1][2].
Industry Recognition and Supply Chain Confidence
The flawless audit outcome has been publicly acknowledged by industry stakeholders, including Fluorochem Ltd, a UK-based chemical manufacturer with decades of experience in pharmaceutical intermediates [2]. Fluorochem noted on 1 November 2026 that ChemExpress’s Ma’anshan facility had achieved zero observations during the FDA inspection, highlighting the site’s capabilities in API and HPAPI manufacturing for international markets [2]. Such endorsements from established chemical supply chain participants reinforce confidence in ChemExpress’s operational reliability and compliance infrastructure [2].